LAURA PONTES: Open Payments
NPI 1770706343 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,966 in 72 payments from 11 companies in 2025. Trend: 2023 $1,683 · 2024 $12,121 · 2025 $5,966
Consulting: $3,450Food & beverage: $1,991Travel & lodging: $467Education: $58
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 8 | $2,898 |
| Janssen Biotech, Inc. | 12 | $1,570 |
| ABBVIE INC. | 29 | $682 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $305 |
| PFIZER INC. | 2 | $216 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| Ardelyx, Inc. | 2 | $54 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: OMVOH, TREMFYA, SKYRIZI, ENTYVIO, VELSIPITY, RINVOQ, CREON, IBSRELA.
Industry payments across TX — which companies pay providers there.
